London, England – A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial. The findings, published in Ophthalmology, describe the efficacy and...
Latest News
Treatment with monoclonal antibodies (mAbs) and anticytokine biologics is not effective in decreasing the frequency of coronary artery aneurysms (CAAs) in patients with Kawasaki disease (KD), but the incidence of treatment resistance may be reduced with these agents compared with conventional intravenous immunoglobulin (IVIG) therapy alone, according to findings from...
Use of a new diagnostic guideline for hypersensitivity pneumonitis (HP), published in 2020, has resulted in half of patients with HP also being diagnosed with idiopathic pulmonary fibrosis (IPF), according to authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine. The investigators who conducted...
FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. Bronchitol® is...
Madrid, Spain – An off-label treatment with subcutaneous efgartigimod helped manage severe, treatment-resistant Lambert-Eaton myasthenic syndrome (LEMS) in a 20-year-old woman in Spain whose condition had left her unable to walk independently or perform basic daily activities. Following treatment, she regained significant mobility and independence, eventually walking 200 meters (656...
Stockholm, Sweden — Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) announced that the Company, as part of its initiatives to increase disease awareness about MCT8 deficiency, has participated and informed about MCT8 deficiency, at the following medical conferences during the first quarter of 2023: British Paediatric Neurology Association (BPNA) Annual...
Stockholm, Sweden – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced the publication (Liao, Marelli et al. 2026; https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00396-8/fulltext) of the largest retrospective cohort study to date of patients with resistance to thyroid hormone beta (RTH-beta) treated with tiratricol (triiodothyroacetic acid or Triac), providing an integrated...
Stockholm, Sweden — Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that its partner Fujimoto Pharmaceutical Corporation, which has an exclusive license agreement to develop and commercialize Emcitate® (tiratricol) for the treatment of MCT8 deficiency in Japan, has been granted Orphan Drug Designation (ODD) for tiratricol...
STOCKHOLM, SWEDEN – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency...
Stockholm, Sweden – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases, today announced the commercial availability of EMCITATE® (tiratricol), ahead of anticipated timelines following U.S. Food and Drug Administration (FDA) approval...